Injectables Segment to Dominate Europe Hypertrophic and Keloid Scar Treatment Market during 2019–2027

According to a new market research study on “Europe Hypertrophic and Keloid Scar Treatment Market to 2027 – COVID-19 Impact and Analysis and Forecast by Scar Type, Product Type, and End User,” is expected to reach US$ 2,705.59 million by 2027 from US$ 1,376.88 million in 2020. The market is estimated to grow at a CAGR of 10.1% from 2020 to 2027. The report provides trends prevailing in the Europe hypertrophic and keloid scar treatment market along with the drivers and restraints pertaining to the market growth. Growing cases of injuries is the major factor driving the growth of the Europe hypertrophic and keloid scar treatment market. However, unavailability of universal treatment due to huge costs, side effects, and scanty awareness may hinder the growth of Europe hypertrophic and keloid scar treatment market.     

Spain, Italy, Germany, France, and the UK are the most affected countries in Europe, owing to the increasing number of COVID-19 cases and deaths. As per the Worldometer, in Spain, Italy, Germany, France, and the UK, the number of cases is 2.25 million, 2.37 million, 2 million, 95 million, 3.36 million, respectively. The number of deaths in these countries is also high. As per the news article, in Italy, due to the COVID-19 emergency, access for thousands of cancer patients in need of chemotherapy, scans, transplants, and surgery has become difficult. There is several issued guidance from national and international organizations trying to help cope with suspected or verified COVID-19 patients. Besides, Germany has prolonged its pandemic prohibitions, including closing schools and shops, until mid-February due to fears that new COVID-19 mutations could cause a further increase in cases. In addition to extending the closing of restaurants, shops, and schools until February 14, Merkel and the governors of Germany's 16 states decided to enable citizens to wear more functional FFP2 or KN95 masks on public transport and supermarkets. Employers would now be ordered to encourage workers to work from home, wherever possible, to prevent office-driven infections. Hypertrophic and keloid scar treatment patients are considered less sensitive from COVID-19 than the general population. Europe has long been within an area of dynamic development in dermatology procedures, adapting to different cultures, traditions, and surgical and medical philosophies. In recent times, these changes have been even more significant and rapid.

The market for hypertrophic and keloid scar treatment market is segmented into scar type, product type, end user, and country. Based on scar type, the hypertrophic and keloid scar treatment market is segmented into hypertrophic and keloid. The hypertrophic segment held the largest share of the market in 2019. Based on product type, the hypertrophic and keloid scar treatment market is segmented into laser products, topical products, injectables, and other products. The injectables segment held the largest share of the market in 2019. Based on topical products, the market is segmented into gels, silicone sheets, creams, other. Based on laser, the market is segmented into CO2, pulse-dyed, other. Based on end user, the hypertrophic and keloid scar treatment market is segmented into hospitals, clinics, and homecare. The hospitals segment held the largest share of the market in 2019. Based on country, the market is segmented into the Germany, UK, France, Italy, Spain, and rest of Europe. Germany held the largest share of the market in 2019.

Alliance Pharma PLC, Mölnlycke Health Care AB., Smith & Nephew, Newmedical Technology Inc., Lumenis, Sonoma Pharmaceuticals, Inc, Suneva Medical, HRA Pharma and Perrigo Company plc are among the leading companies in the Europe hypertrophic and keloid scar treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Mölnlycke announces the launch of a new UK distribution centre to strengthen customers' access to quality Mölnlycke products through a new, more robust supply chain solution that delivers environmental benefits.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com